Overview

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Exenatide
Criteria
Inclusion Criteria:

- Subjects with Type 2 diabetes mellitus

- Treated with a sulfonylurea at defined doses for at least 3 months prior to screening

- BMI= 27-45 kg/m2

- HbA1c value between 7.5% and 11%

Exclusion Criteria:

- Treated with oral anti-diabetic medications other than a sulfonylurea within 3 months
of screening

- Patients treated previously with AC2993

- Patients presently treated with insulin